JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Silencing of Mutant p53 Leads to Suppression of Human Breast Xenograft Tumor Growth in vivo
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : KSBB Journal
  • Volume 31, Issue 1,  2016, pp.52-57
  • Publisher : Korean Society for Biotechnology and Bioengineering
  • DOI : 10.7841/ksbbj.2016.31.1.52
 Title & Authors
Silencing of Mutant p53 Leads to Suppression of Human Breast Xenograft Tumor Growth in vivo
Park, Won Ick; Park, Se-Ra; Park, Hyun-Joo; Bae, Yun-Hee; Ryu, Hyun Su; Jang, Hye-Ock; Bae, Moon-Kyoung; Bae, Soo-Kyung;
  PDF(new window)
 Abstract
Mutant p53 (R280K) is highly expressed in MDA-MB-231 triple-negative human breast cancer cells. Currently, we reported the role of mutant p53-R280K in mediating the survival of MDA-MB-231 cells in vitro. The present study was undertaken to determine whether mutant p53-R280K affects breast cancer cell growth in vivo. To this end, we used small interfering RNA to knockdown the level of mutant p53-R280K in MDA-MB-231 cells. Silencing of mutant p53-R280K in MDA-MB-231 cells causes substantial tumor regression of established xenografts in vivo. In xenograft model for breast cancer, silencing of mutant p53-R280K in MDA-MB-231 cells significantly inhibited the tumor growth. Moreover, TUNEL assay showed more occurrence of apoptotic cells in mutant p53-R280K silenced tumors compared to control. Our data indicate that mutant p53-R280K has an important role in mediating tumor growth of MDA-MB-231 cells in vivo. Taken together, this study suggests that endogenous mutant p53-R280K could be used as a therapeutic target for breast cancer cells harboring this TP53 missense mutation.
 Keywords
Mutant p53;Breast cancer;Apoptosis;Xenograft tumor model;
 Language
Korean
 Cited by
 References
1.
Selivanova, G. (2004) P53: Fighting Cancer. Curr. Cancer. Drug Targets 4: 385-402. crossref(new window)

2.
Horn, H. F. and K. H. Vousden (2007) Coping with stress: multiple ways to activate p53. Oncogene. 26: 1306-1316. crossref(new window)

3.
Molchadsky, A., N. Rivlin, R. Brosh, V. Rotter, and R. Sarig (2010) P53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis. 31: 1501-1508. crossref(new window)

4.
Brosh, R. and V. Rotter (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer. 9: 701-713.

5.
Walerych, D., M. Napoli, L. Collavin, and G. Del-Sal (2012) The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 33: 2007-2017. crossref(new window)

6.
Wijnhoven, S. W., E. N. Speksnijder, X. Liu, E. Zwart, C. T. van Oostrom, R. B. Beems, E. M. Hoogervorst, M. M. Schaap, L. D. Attardi, T. Jacks, H. van Steeg, J. Jonkers, and A. deVries (2007) Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res. 67: 4648-4656. crossref(new window)

7.
Mehta, S. A., K. W. Christopherson, P. Bhat-Nakshatri, J. R. Goulet-RJ, H. E. Broxmeyer, L. Kopelovich, and H. Nakshatri (2007) Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene. 26: 3329-3337. crossref(new window)

8.
Zhu, H. B., K. Yang, Y. Q. Xie, Y. W. Lin, Q. Q. Mao, and L. P. Xie (2013) Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J. Surg. Oncol. 28: 11-22.

9.
Lim, L. Y., N. Vidnovic, L. W. Ellisen, and C. O. Leong (2009) Mutant p53 mediates survival of breast cancer cells. Br. J. Cancer. 101: 1606-1612. crossref(new window)

10.
Bayraktar, S. and S. Gluck (2013) Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res. Treat. 138: 21-35. crossref(new window)

11.
Bae, Y. H., J. H. Ryu, H. J. Park, K. R. Kim, H. J. Wee, O. H. Lee, H. O. Jang, M. K. Bae, K. W. Kim, and S. K. Bae (2013) Mutant p53-notch1 signaling axis is involved in curcumin-induced apoptosis of breast cancer cells. Korean J. Physiol. Pharmacol. 17: 291-297. crossref(new window)

12.
Bae, Y. H., J. M. Shin, H. J. Park, H. O. Jang, M. K. Bae, and S. K. Bae (2014) Gain-of-function mutant p53-R280K mediates survival of breast cancer cells. Genes & Genomics 36: 171-178. crossref(new window)